v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue $ 1,474 $ 1,163 $ 2,730 $ 1,991
Operating expenses:        
Cost of revenue 1,445 1,563 3,070 3,114
Sales and marketing 5,776 4,007 10,777 8,076
General and administrative 5,757 5,617 11,188 11,779
Amortization of acquired intangible assets 105 105 210 210
Research and development 1,192 1,255 2,399 2,683
Total operating expenses 14,275 12,547 27,644 25,862
Operating loss (12,801) (11,384) (24,914) (23,871)
Other income (expense):        
Interest income 77 110 147 176
Interest expense (4) (6) (10) (14)
Change in fair value - Senior Secured Convertible Note 1,041 6,841 (819) (7,638)
Other income (expense), net 1,114 6,945 (682) (7,476)
Loss before provision for income tax (11,687) (4,439) (25,596) (31,347)
Provision for income taxes 0 0 0 0
Net loss attributable to Lucid Diagnostics Inc. (11,687) (4,439) (25,596) (31,347)
Less: Series B Convertible Preferred Stock dividends earned (3,028) (3,449) (12,747) (12,559)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (14,715) $ (7,888) $ (38,343) $ (43,906)
Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted (in dollars per share) [1] $ (0.08) $ (0.08) $ (0.24) $ (0.52)
Weighted average common shares outstanding, basic and diluted (in shares) 183,124,412 98,989,161 161,729,458 83,976,182
[1] Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.